Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. One development candidate is TELINTRA® (TLK199) which is currently in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia.  TELINTRA® is also being evaluated for the treatment of additional blood disorders.  Another product candidate, TELCYTA® (TLK286), is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer. These product candidates, and the other candidates in our pipeline, were discovered using our proprietary technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Investor Info

2012 Annual Report

2014 Proxy Statement

2013 Proxy Statement

Latest News

May 10, 2013
Telik Announces First Quarter 2013 Financial Results

March 15, 2013
Telik Announces Fourth Quarter and 2012 Year End Financial Results and 2013 Financial Guidance

January 22, 2013
Telik Announces Preliminary Agreement on Design of Phase 3 Registration Trial of Telintra® in Low to Intermediate-1 Risk Myelodysplastic Syndrome

January 11, 2013
Telik Announces Orphan Designation of Telintra® for Treatment of Myelodysplastic Syndrome

December 12, 2012
Telik Announces Telintra® Clinical Publication at the 54th Annual Meeting of the American Society of Hematology








Sitemap Contact Legal Notice Telik Home